Cytogel Pharma vs Tempus
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cytogel Pharma is a clinical-stage biotech developing CYT-1010, a first-in-class endomorphin-based analgesic for non-addictive pain relief; targets the opioid epidemic with a novel peptide mechanism that provides pain control without addiction risk.
About
Cytogel Pharma is a clinical-stage biopharmaceutical company developing novel, non-addictive pain management therapies as alternatives to traditional opioids. Its lead drug candidate, CYT-1010, is a first-in-class endomorphin-based analgesic — a synthetic peptide that activates opioid receptors in the brain and spinal cord to produce effective analgesia while minimizing or eliminating the euphoric and addictive properties of conventional opioids like oxycodone and morphine.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
About
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.